March 5, 2014 | Israeli drug development company BiolineRX is planning a secondary offering on Nasdaq, in an attempt to raise $21 million. The company will use the proceeds for a Phase II clinical trial of its leukemia treatment and a Phase I clinical trial of its celiac disease treatment.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts

Red Algae Can Treat Wounds And Infections
January 26, 2023

Freight Planner Lists on Nasdaq And Raises $80M
January 26, 2023

$6M Investment For “Lettuce Milk” Startup
January 25, 2023

Israel Has World’s Best Value Internet
January 25, 2023
Facebook comments